Segui
Veronica Giusti
Veronica Giusti
PhD student, Univercity of Bologna
Email verificata su unibo.it
Titolo
Citata da
Citata da
Anno
Virus-like particle display of HER2 induces potent anti-cancer responses
A Palladini, S Thrane, CM Janitzek, J Pihl, SB Clemmensen, ...
Oncoimmunology 7 (3), e1408749, 2018
1022018
Bone sarcoma patient-derived xenografts are faithful and stable preclinical models for molecular and therapeutic investigations
P Nanni, L Landuzzi, MC Manara, A Righi, G Nicoletti, C Cristalli, ...
Scientific Reports 9 (1), 12174, 2019
542019
HER2 isoforms co-expression differently tunes mammary tumor phenotypes affecting onset, vasculature and therapeutic response
A Palladini, G Nicoletti, A Lamolinara, M Dall’Ora, T Balboni, ML Ianzano, ...
Oncotarget 8 (33), 54444, 2017
252017
Integrated molecular characterization of patient-derived models reveals therapeutic strategies for treating CIC-DUX4 sarcoma
M Carrabotta, MA Laginestra, G Durante, C Mancarella, L Landuzzi, ...
Cancer research 82 (4), 708-720, 2022
182022
CCN proteins in the musculoskeletal system: current understanding and challenges in physiology and pathology
V Giusti, K Scotlandi
Journal of Cell Communication and Signaling 15 (4), 545-566, 2021
152021
Evolution of HER2-positive mammary carcinoma: HER2 loss reveals claudin-low traits in cancer progression
V Giusti, F Ruzzi, L Landuzzi, ML Ianzano, R Laranga, E Nironi, ...
Oncogenesis 10 (11), 77, 2021
152021
Early stability and late random tumor progression of a HER2-positive primary breast cancer patient-derived xenograft
L Landuzzi, A Palladini, C Ceccarelli, S Asioli, G Nicoletti, V Giusti, ...
Scientific reports 11 (1), 1563, 2021
82021
Virus-like particle display of HER2 induces potent anti-cancer responses. Oncoimmunology 7, e1408749
A Palladini, S Thrane, CM Janitzek, J Pihl, SB Clemmensen, ...
72018
Extracellular vesicle-associated IGF2BP3 tunes Ewing sarcoma cell migration and affects PI3K/Akt pathway in neighboring cells
C Mancarella, V Giusti, G Caldoni, MA Laginestra, A Parra, L Toracchio, ...
Cancer Gene Therapy 30 (9), 1285-1295, 2023
12023
Functional stability, progression and evolution of targeted drug sensitivity of HER-2-positive breast cancer patient-derived xenografts
L Landuzzi, ML Ianzano, C Ceccarelli, ED Oto, G Nicoletti, V Giusti, ...
Cancer Research 78 (13_Supplement), 216-216, 2018
12018
Preclinical Development of novel therapeutic approaches in models resistant to targeted therapies in HER2-positive mammary breast cancer
V Giusti
alma, 2019
2019
A novel virus-like particle vaccine presenting HER-2 extracellular domain elicits strong immune responses against mammary carcinoma
A Palladini, S Thrane, CM Janitzek, J Pihl, SB Clemmensen, WA Jongh, ...
Cancer Research 78 (13_Supplement), 716-716, 2018
2018
HER2 cancer vaccine optimization by combining Drosophila S2 insect cell manufacturing with a novel VLP-display technology
T Jørgensen, M Soegaard, A Palladini, S Thrane, CM Janitzek, J Pihl, ...
2018
HER-2 isoform interaction in mammary carcinoma onset and progression
A Palladini, M Dall’Ora, T Balboni, G Nicoletti, M Ianzano, R Laranga, ...
Cancer Research 76 (14_Supplement), 1200-1200, 2016
2016
Il sistema al momento non può eseguire l'operazione. Riprova più tardi.
Articoli 1–14